Phesi finds fewer than 1 in 3 trial protocols connect to real patient data — meaning flawed assumptions reach...

Infex's RESP-X Phase IIa bronchiectasis study shows efficacy signal, lung deposition, and clean safety profile supporting Phase IIb/III advancement.

Aktis Oncology reports AKY-2519 dosimetry data showing predicted salivary gland dose of 4.2 Gy RBE, addressing a key toxicity...

TaiMed completes Phase 2b enrollment for TMB-365/380 HIV regimen ahead of schedule, with interim readout expected before end of...

A rare gene therapy-linked cancer case exposes the gap between FDA's 15-year CAR-T surveillance mandate and real-world monitoring systems...

BIIB122 achieved strong target engagement but failed to slow Parkinson's disease progression in the Phase 3 LUMA trial, raising...

Tedopi with pembrolizumab extended median PFS to 4.1 months in platinum-resistant ovarian cancer patients with no remaining standard treatment...

Aktis Oncology reports first-in-human data for AKY-2519 in B7-H3 tumors, showing predicted salivary gland dose of 4.2 Gy RBE...

China approves toripalimab plus disitamab vedotin for HER2+ urothelial cancer, doubling progression-free survival versus chemotherapy in Phase 3 trial.

RESP-X shows safety and reduced exacerbations in bronchiectasis study targeting Pseudomonas aeruginosa via PcrV inhibition.